Nanollose Limited (ASX:NC6) is pleased to announce that in addition to the non-binding Memorandum of Understanding signed in April 2018, a binding research agreement has been executed with Indonesian food producer, PT Supra Natami Utama.
Rhinomed Limited (ASX:RNO) (OTCMKTS:RHNMF) a nasal delivery technology company has successfully undertaken a placement to institutional and sophisticated domestic and international investors at $0.21 per share. The company sought to raise a minimum of A$3.0 million and up to a maximum of A$5.0m and is pleased to report that demand saw the raise close at $A5.0 million.
Queensland Bauxite Ltd (ASX:QBL) provides the Company's Quarterly Activities Report.
Queensland Bauxite Ltd (ASX:QBL) provides the Company's cover note and second supplementary prospectus.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce John Martin, CEO, will present at the AusBiotech 2018 Conference today.
Nanollose Limited (ASX:NC6) is pleased to provide its Appendix 4C cash flow statement for the quarter ending 30 September 2018, together with the following operational update.
Rhinomed (ASX:RNO) (OTCMKTS:RHNMF) a leader in nasal delivery technology, today announced its 7th consecutive quarter on quarter of revenue growth. Positive trading conditions saw unaudited recognised revenues increase 30% over FY18 Q4 to $1.14m for FY19 Q1.
